世界最新医学信息文摘（连续型电子期刊）
世界最新醫學信息文摘（連續型電子期刊）
세계최신의학신식문적（련속형전자기간）
World Latest Medicine Information
2015年
73期
42-43
,共2页
神经性耳聋耳鸣%治疗方法%颈中交感神经节阻滞
神經性耳聾耳鳴%治療方法%頸中交感神經節阻滯
신경성이롱이명%치료방법%경중교감신경절조체
nervous deafness tinnitus%treatment method%cervical sympathetic ganglia block
目的:研讨神经性耳聋耳鸣的临床治疗方法及效果.方法:随机将我院近两年时间诊疗的74例神经性耳聋耳鸣病例分组,对照组37例单纯予常规药物治疗,观察组37例合用颈中交感神经节阻滞治疗,针对两组的患耳治疗情况作比较和评估.结果:在临床疗效上,观察组总治愈率89.2%,与对照组的70.3%相比明显增高,有显著差异(P<0.05).两组诊疗期间均未见严重不良反应出现,但在复发率上,观察组有2.7%的患者复发,相比对照组的16.2%明显降低,有显著差异(P<0.05).结论:合用颈中交感神经节阻滞与常规药物治疗神经性耳聋耳鸣具有较安全的疗效,且复发率低,适合在临床推广.
目的:研討神經性耳聾耳鳴的臨床治療方法及效果.方法:隨機將我院近兩年時間診療的74例神經性耳聾耳鳴病例分組,對照組37例單純予常規藥物治療,觀察組37例閤用頸中交感神經節阻滯治療,針對兩組的患耳治療情況作比較和評估.結果:在臨床療效上,觀察組總治愈率89.2%,與對照組的70.3%相比明顯增高,有顯著差異(P<0.05).兩組診療期間均未見嚴重不良反應齣現,但在複髮率上,觀察組有2.7%的患者複髮,相比對照組的16.2%明顯降低,有顯著差異(P<0.05).結論:閤用頸中交感神經節阻滯與常規藥物治療神經性耳聾耳鳴具有較安全的療效,且複髮率低,適閤在臨床推廣.
목적:연토신경성이롱이명적림상치료방법급효과.방법:수궤장아원근량년시간진료적74례신경성이롱이명병례분조,대조조37례단순여상규약물치료,관찰조37례합용경중교감신경절조체치료,침대량조적환이치료정황작비교화평고.결과:재림상료효상,관찰조총치유솔89.2%,여대조조적70.3%상비명현증고,유현저차이(P<0.05).량조진료기간균미견엄중불량반응출현,단재복발솔상,관찰조유2.7%적환자복발,상비대조조적16.2%명현강저,유현저차이(P<0.05).결론:합용경중교감신경절조체여상규약물치료신경성이롱이명구유교안전적료효,차복발솔저,괄합재림상추엄.
Objective: To study the clinical treatment methods and effects of the tinnitus of nervous deafness.Methods:74 cases of nervous deafness in our hospital during the past two years, 37 cases of the control group were treated with conventional drugs, 37 cases were treated with cervical sympathetic ganglion block, and the two groups were compared and evaluated. Results:the total cure rate of the observation group was 89.2%, which was significantly higher than that of the control group (P< 0.05), which was significantly higher than that in control group (< 70.3%). No serious adverse reactions occurred in the two groups, but in the recurrence rate, the observation group had 2.7% of patients relapse, compared to the control group of 16.2%significantly lower, there was a significant difference (P < 0.05).Conclusion: the combination of cervical sympathetic ganglia block and conventional drugs in the treatment of nervous deafness tinnitus has a relatively safe, and the recurrence rate is low, suitable for clinical promotion.
